At the 44th Annual J.P. Morgan Healthcare Conference, Twist Bioscience (TWST) CEO Dr. Emily Leproust and CFO Adam Laponis outlined the company’s strategic positioning in life science tools. Dr. Leproust emphasized Twist’s semiconductor-based DNA synthesis platform, noting its precision, high throughput and cost efficiency in multibillion-dollar end markets. The company serves more than 4,000 customers, including top-tier pharmaceutical, biotech and agricultural institutions, with applications spanning therapeutic drug discovery, molecular diagnostics, sustainable chemical production via engineered yeast and algae, and food-security trait development in plants and animals. Twist projects continued expansion across its DNA synthesis, protein engineering and next-generation sequencing segments, underscoring its emerging leadership in global life science tools.

Twist Bioscience reported preliminary, unaudited revenue for the quarter ended December 31, 2025, and confirmed that full financial results will be released before market open on February 2, 2026. The company has scheduled a conference call and live webcast for analysts and investors at 8:00 a.m. Eastern Time that day, with telephone participants required to register in advance to receive dial-in credentials. Management indicated that the webcast replay will remain available on the Investor Relations section of the company website for two weeks, facilitating broad access for investors seeking updates on revenue trends, operating margins and cash-flow trajectory as TWST continues to scale its silicon-based synthesis platform.